DXCM DEXCOM INC.

Dexcom Expands AID Partnership Into The Netherlands

DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring for people with diabetes, today announced that people living with Type 1 diabetes in the Netherlands will be able to use a new tubeless Hybrid Closed Loop system (HCL) the Omnipod® 5 integrated with the Dexcom G6 Continuous Glucose Monitor (CGM), for an easier1-3 diabetes management experience. In the Netherlands, 100,000 people have type 1 diabetes, with an estimated 10,000 children affected*, making it the most common autoimmune disease among children after asthma 4. Type 1 diabetes can be challenging for anyone to manage and live with, but for children with Type 1, and their families, everyday activities such as exercising, eating, and swimming can be even more challenging. The Omnipod® 5 tubeless insulin pump integrated with the Dexcom G6 CGM can simplify their lives by offering easier1-2,4 diabetes management whilst allowing families, friends, and carers to remotely check glucose levels with the unique to Dexcom ‘Follow’ app||.

Research2 published in Diabetes Care shows that use of this Hybrid Closed Loop system (HCL) significantly increased time in range (+11.5%) and reduced HbA1c and time in hypoglycemia (<70 mg/dL) in very young children (aged 2 – 5.9 years) with Type 1 diabetes. The same study also saw adult participants spend an additional 11.8% more time in range. These significant and clinically meaningful health outcomes are only proven when the Omnipod® 5 HCL system is integrated with Dexcom CGM.

Paediatrician Maartje Wijers-van Amelsfort M.D. from the Slingeland hospital in Doetinchem, said: “Thanks to sensors like the Dexcom G6 we can use more and more data to keep track of our patients’ diabetes. The rise of AID helps in that too. We can better monitor and adjust our treatment where necessary. This makes it easier to manage diabetes.”

Unique features give people more flexibility

For adults and children with Type 1 diabetes, this new Dexcom G6 and Omnipod® 5 hybrid closed loop system, is an important step in improving their diabetes management . The system is the first tubeless HCL in the Netherlands approved for children, offering discretion and freedom to move without concern about tubes snagging or being pulled out. However, perhaps of most interest to parents or caregivers is the, unique to Dexcom, ‘Follow’ app that allows Dexcom CGM users to simultaneously connect to their Omnipod® 5 pump whilst sharing their glucose data in real time with up to 10 followers, offering everyone a little more peace of mind||. Moreover, with Dexcom G6§, the on-body parts of the system have a high-level of water resistance**, so exercising and playing in swimming pools, seas and lakes becomes much easier.

Most connected diabetes sensor

Emphasising Dexcom’s position as a leader in integrating connected systems, Dexcom G6 was exclusively used in the clinical trials that led to the regulatory approval of Omnipod® 5 in Europe, Canada, and the United States2,5. Dexcom offers users choice and flexibility when it comes to how they manage their diabetes and view glucose levels. For example, Dexcom CGM also links# with multiple insulin pumps, digital health apps, lifestyle devices such as Garmin and Apple. All these options give people with diabetes freedom in managing the disease and making the right choice for them when it comes to appropriate care.

Dexcom G6 is available for reimbursement in the Netherlands via health insurers for children (18 and under), pregnant women (Type 1 and Type 2), women trying for pregnancy, and Type 1 hypo unaware users. Those interested in the HCL system should speak to their healthcare provider or visit dexcom.nl for more information.

About DexCom, Inc.

DexCom, Inc. empowers people to take real-time control of health through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, Calif., and with operations in the Netherlands, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom works to simplify and improve diabetes management around the world. For more information about Dexcom CGM, visit .

Dexcom Data on File, 2024.

* Netherlands Institute for Healthcare Research & National Institute for Public Health and the Environment, Diabetes Mellitus in the Netherlands 2020, 13

§ The Dexcom G6 sensor and transmitter are water-resistant and may be submerged under up to 2.4m of water for up to 24 hours without failure when properly installed.

** The Pod has a waterproof IP28 rating for up to 25 feet for 60 minutes. The Omnipod 5 Controller are not waterproof.

†Compared to patients not using an AID system

||Separate Dexcom Follow app and internet connection required. Users should always confirm measurements on the Dexcom [G6 app or receiver before making a treatment decision.

¶ Time in target range was defined as time within a glucose range of 3.9-10.0 mmol/L - 70-180 mg/dL.

#The extensive list of compatible devices can be found at:

1 Brown SA, et al. N Engl J Med. 2019;381(18):1707-1717. 2 Brown SA, et al. Diabetes Care. 2021;44(7):1630-1640. 3 Diabetes Fonds. Diabetes in Numbers. diabetsfonds.nl Accessed June, 2024. 4 Sherr, J.L, et al. Diabetes Care 2022; 45(8):1907-1910

EN
20/06/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on DEXCOM INC.

Dexcom Inc: 3 directors

Two Directors at Dexcom Inc sold 3,250 shares at between 82.800USD and 83.129USD. The significance rating of the trade was 45/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last t...

Research Team ACF
  • Research Team ACF

KDST + NLSP Combined Core Investment Case 29052025

We consider the merged platform Kadimastem (KDST.TA) + NLS Pharmaceutics (NLSP:NasdaqCM). We provide an investment case analysis and a selection of merged metrics prior to any synergies. The merger creates a cross-platform pre-revenue biotech with lead programs including a proprietary stem-differentiation platform capable of delivering scalable therapies for replacing lost or damaged cells; IsletRx could revolutionize insulin production for Type 1 diabetes (T1D) patients; AstroRx® targets neurod...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

OSK OSHKOSH CORP
DXCM DEXCOM INC.
XRAY DENTSPLY SIRONA INC.
WING WINGSTOP INC.
VRTS VIRTUS INVESTMENT PARTNERS INC.
UHS UNIVERSAL HEALTH SERVICES INC. CLASS B
STKS ONE GROUP HOSPITALITY
SNPS SYNOPSYS INC.
SMG SCOTTS MIRACLE-GRO COMPANY CLASS A
SFST SOUTHERN FIRST BANCSHARES
RGNX REGENXBIO INC.
RCKY ROCKY BRANDS
PRGO PERRIGO CO. PLC
MPWR MONOLITHIC POWER SYSTEMS INC.
JRVR JAMES RIVER GROUP HOLDINGS LTD
IRM IRON MOUNTAIN INC.
GPC GENUINE PARTS COMPANY
GD GENERAL DYNAMICS CORPORATION
DLTR DOLLAR TREE INC.
DG DOLLAR GENERAL CORPORATION
CROX CROCS INC.
CAL CALERES INC.
BKE BUCKLE INC.
ASC ARDMORE SHIPPING
AMOT ALLIED MOTION TECHNOLOGIES
ACAD ACADIA PHARMACEUTICALS INC.
SBL SAFE BULKERS INC.
LPG DORIAN LPG
MEG. MEG ENERGY CORP.
MDU MDU RESOURCES GROUP INC
NAT NORDIC AMERICAN TANKERS LIMITED
EVTC EVERTEC INC.
FSLR FIRST SOLAR INC.
IONS IONIS PHARMACEUTICALS INC.
NMIH NMI HOLDINGS INC. CLASS A
AGYS AGILYSYS INC.
SJM J.M. SMUCKER COMPANY
FIZZ NATIONAL BEVERAGE CORP.
NHC NATIONAL HEALTHCARE CORP.
INSW INTERNATIONAL SEAWAYS INC.
FLGT FULGENT GENETICS
DK DELEK US HOLDINGS INC
CELH CELSIUS HOLDINGS INC.
AMD ADVANCED MICRO DEVICES INC.
TTEC TTEC HOLDINGS INC.
AVGO BROADCOM INC.
ST SENSATA TECHNOLOGIES HOLDING PLC
ELAN ELANCO ANIMAL HEALTH INC.
MEC MAYVILLE ENGINEERING
DELL DELL TECHNOLOGIES INC CLASS C
CSTM CONSTELLIUM SE CLASS A
OI O-I GLASS INC
BWMN BOWMAN CONSULTING GROUP LTD
DINO HOLLYFRONTIER CORP
EVEX EVE HOLDING INC
SPXC SPX TECHNOLOGIES INC
WEST WESTROCK COFFEE COMPANY LLC
ADCT ADC THERAPEUTICS SA
SVV SAVERS VALUE VILLAGE INC
GUTS FRACTYL HEALTH INC
AGEN AGENUS INC.
ARDT ARDENT HEALTH PARTNERS INC
PCT PROVIDENT CAP TR II SKIS 8.75%29
MKTW MARKETWISE INC
 PRESS RELEASE

Dexcom Report Unveiled at ATTD 2025 Reveals HCPs Favour Tech Over Medi...

EDINBURGH, Scotland & SAN DIEGO--(BUSINESS WIRE)-- (NASDAQ: DXCM), a global leader in glucose biosensing, today announced the launch of its first multi-region report, the "Dexcom State of Type 2 Report: Access and Attitudes Across Europe and the Middle East." The report surveyed over 2,500 people, made up of individuals with Type 2 diabetes and healthcare professionals, from Germany, Italy, the Netherlands, Saudi Arabia, Spain and the United Kingdom. The findings provide valuable insights into access to care and perceptions of diabetes technology. During the conference, first-ever accuracy a...

Research Team ACF
  • Research Team ACF

ACF Thematic Research Regenerative Medicine Diabetes Treatment & Innov...

Diabetes mellitus, Type 1 (T1D) and Type 2 (T2D, 85-90% of cases), is a USD ~75bn global therapy market. Global economic costs of diabetes may exceed USD1 trn today and USD 450bn in the US, suggesting a pressing global health challenge. Diabetes is a chronic metabolic disorder characterized by high blood sugar levels. In 2024, consensus global estimates suggested there were ~800m adult diabetes sufferers. In 2021, according to the IDF there >530m sufferers globally. For 2027E we modestly forecas...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch